Edgar Filing: ARRAY BIOPHARMA INC - Form 5

ARRAY BIOPHARMA INC Form 5 August 15, 2011 FORM 5

1(b).

Form 4

(Last)

(City)

OMB APPROVAL OMB UNITED STATES SECURITIES AND EXCHANGE COMMISSION 3235-0362 Number: Washington, D.C. 20549 Check this box if January 31, Expires: no longer subject 2005 to Section 16. Estimated average ANNUAL STATEMENT OF CHANGES IN BENEFICIAL Form 4 or Form burden hours per 5 obligations **OWNERSHIP OF SECURITIES** response... 1.0 may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Form 3 Holdings Section 17(a) of the Public Utility Holding Company Act of 1935 or Section Reported 30(h) of the Investment Company Act of 1940 Transactions Reported 1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading 5. Relationship of Reporting Person(s) to Issuer CARUTHERS MARVIN H Symbol ARRAY BIOPHARMA INC (Check all applicable) [ARRY] (Middle) 3. Statement for Issuer's Fiscal Year Ended (First) _X_ Director 10% Owner Officer (give title Other (specify (Month/Day/Year) below) below) 06/30/2011 C/O 3200 WALNUT STREET (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Reporting Filed(Month/Day/Year) (check applicable line) _X_ Form Filed by One Reporting Person Form Filed by More than One Reporting Person (State) (Zin

(City)	(State) (Zip) Tabl	e I - Non-Deri	vative Sec	urities	s Acqui	red, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit (A) or Dis (D) (Instr. 3, 4)	sposed	l of	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/14/2011	Â	$G^{(1)}$	88,437	D	\$0	271,340	Ι	Held by GRAT
Common Stock	04/14/2011	Â	G <u>(1)</u>	88,437	А	\$0	177,763	D	Â
Common Stock	Â	Â	Â	Â	Â	Â	131	I	Held in Family LLC

Edgar Filing: ARRAY BIOPHARMA INC - Form 5

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 2270 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3,	Number Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D)		7. Titl Amou Under Secur (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	9. of D Se B O E I S Fi (I
				4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
i o	Director	rector 10% Owner		Other			
CARUTHERS MARVIN H C/O 3200 WALNUT STREET BOULDER, CO 80301	ÂX	Â	Â	Â			
Signatures							
R. Michael Carruthers, attorney-in-fact for Reporting 08/15/2011							
<u>**</u> Signature of Reportir	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This gift was erroneously reported on a Form 4 on August 15, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.